Methylphenidate effects on a clinically informative oscillatory signal within the subthalamic nucleus in Parkinson's disease during deep brain stimulation programming

Kern, Drew S.; Korsmo, Michael; Baumgartner, Alexander J.; Kramer, Daniel R.; Ojemann, Steven G.; Case, Michelle; Holt-Becker, Abbey; Raike, Robert S.; Thompson, John A.

doi:10.1016/j.brs.2022.04.019

Cited by 4 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial and subsequent stimulation settings and sensing parameters are found in Table 2, and further details of this case have been described elsewhere. 40 In this subject, LFP recordings demonstrated consistent uctuations both before and after the change in parameters. These data are shown in Fig.…”

Section: Resultsmentioning

confidence: 61%

“…He was asked to wean and then discontinue taking methylphenidate, which had been prescribed previously for fatigue. 40 Subsequently, BrainSense survey performed 10 days after initial programming revealed more prominent beta peaks in both hemispheres than had been seen previously, with the highest power in contact 2 in both the left and right STN. These changes improved his mood and personality changes within days.…”

Section: Resultsmentioning

confidence: 69%

See 1 more Smart Citation

Diurnal fluctuations of local field potentials follow sleep-wake behavior in Parkinson's disease

Baumgartner

Hirt

Kern

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Sleep disturbances are among the most common non-motor symptoms of Parkinson’s disease (PD). Deep brain stimulation (DBS) of the subthalamic nucleus (STN) reduces local field potential (LFP) activity in the STN, particularly in the beta frequency range (13 – 30 Hz). Although well-characterized in the short term, little is known about how beta frequency oscillations change chronically, across the sleep-wake cycle. Better understanding of these pathological signals in sleep may permit optimization of stimulation to improve sleep in PD. Objectives: Here, we sought to characterize LFPs over several days and nights while patients remained in the home setting. Methods: LFPs were recorded from the subthalamic nucleus in 13 PD subjects (18 hemispheres) over an average of 14.7 ± 4.2 days. Fluctuations in LFP activity were characterized by arousal state, as determined by actigraphy. Results: Beta frequency LFPs showed a clear and consistent diurnal pattern. In all subjects, beta power was higher during wakefulness than during sleep, with little overlap in the magnitude of beta power between these two activity states. LFP snapshots obtained across a broad frequency range at subject-indicated going-to-bed and waking-up times showed significant differences in power across multiple canonical frequency bands, though these differences were not significant at the group level. Conclusions: Beta frequency LFPs fluctuate in a clear and consistent manner that is closely linked to time of day and to activity state. These fluctuations can be detected in the home setting using commercially available devices, including in patients who have been treated with deep brain stimulation for several years.

show abstract

Section: Resultsmentioning

confidence: 61%

Section: Resultsmentioning

confidence: 69%

Diurnal fluctuations of local field potentials follow sleep-wake behavior in Parkinson's disease

Baumgartner

Hirt

Kern

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Evidence is building that BrainSense may be used to guide DBS programming setup and optimization in movements disorders and epilepsy (Feldmann et al, 2021 ; Buijink et al, 2022 ; Fasano et al, 2022 ; Strelow et al, 2022 ; Chua et al, 2023 ; Swinnen et al, 2023 ). Recent studies in Parkinson's disease suggest BrainSense can be used to streamline and reduce the time for initial DBS programming (Binder et al, 2023 ; Lewis et al, 2023 ), troubleshoot difficult cases, identify medication interactions, and mitigate potential overstimulation (Kern et al, 2022 ; Vaou et al, 2023 ). Simplified data visualizations are also being developed to expand access to the insights learned to date (Thompson et al, 2023 ).…”

Section: Advances In Commercially Available Neuromodulation Technologiesmentioning

confidence: 99%

Proceedings of the 11th Annual Deep Brain Stimulation Think Tank: pushing the forefront of neuromodulation with functional network mapping, biomarkers for adaptive DBS, bioethical dilemmas, AI-guided neuromodulation, and translational advancements

Johnson,

Dosenbach,

Gordon

et al. 2024

Front. Hum. Neurosci.

Self Cite

View full text Add to dashboard Cite

The Deep Brain Stimulation (DBS) Think Tank XI was held on August 9–11, 2023 in Gainesville, Florida with the theme of “Pushing the Forefront of Neuromodulation”. The keynote speaker was Dr. Nico Dosenbach from Washington University in St. Louis, Missouri. He presented his research recently published in Nature inn a collaboration with Dr. Evan Gordon to identify and characterize the somato-cognitive action network (SCAN), which has redefined the motor homunculus and has led to new hypotheses about the integrative networks underpinning therapeutic DBS. The DBS Think Tank was founded in 2012 and provides an open platform where clinicians, engineers, and researchers (from industry and academia) can freely discuss current and emerging DBS technologies, as well as logistical and ethical issues facing the field. The group estimated that globally more than 263,000 DBS devices have been implanted for neurological and neuropsychiatric disorders. This year's meeting was focused on advances in the following areas: cutting-edge translational neuromodulation, cutting-edge physiology, advances in neuromodulation from Europe and Asia, neuroethical dilemmas, artificial intelligence and computational modeling, time scales in DBS for mood disorders, and advances in future neuromodulation devices.

show abstract

“…Moreover, studies across multiple centers demonstrate the capability of Percept ™ PC to routinely detect LFP signals of interest in PD, ET, dystonia, OCD and epilepsy subjects with standard of care procedures ( Fasano et al, 2021 ; Goyal et al, 2021 ; Thenaisie et al, 2021 ; Buijink et al, 2022 ; Vissani et al, 2022 ), which is also consistent with prior studies using investigational recording devices ( Case et al, 2020 ; Darcy et al, 2022 ). Further, there is a growing body of case studies demonstrating the application of brain sensing for personalized treatment including initial DBS programming ( Fasano et al, 2021 ; Sirica et al, 2021 ), DBS and medication optimization ( Kern et al, 2022 ), and even understanding circadian patterns ( van Rheede et al, 2022 ).…”

Section: Cutting Edge Technologies From the Industry Sectormentioning

confidence: 99%

Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation

Wong

Mayberg

Wang

et al. 2023

Front. Hum. Neurosci.

View full text Add to dashboard Cite

The deep brain stimulation (DBS) Think Tank X was held on August 17–19, 2022 in Orlando FL. The session organizers and moderators were all women with the theme women in neuromodulation. Dr. Helen Mayberg from Mt. Sinai, NY was the keynote speaker. She discussed milestones and her experiences in developing depression DBS. The DBS Think Tank was founded in 2012 and provides an open platform where clinicians, engineers and researchers (from industry and academia) can freely discuss current and emerging DBS technologies as well as the logistical and ethical issues facing the field. The consensus among the DBS Think Tank X speakers was that DBS has continued to expand in scope however several indications have reached the “trough of disillusionment.” DBS for depression was considered as “re-emerging” and approaching a slope of enlightenment. DBS for depression will soon re-enter clinical trials. The group estimated that globally more than 244,000 DBS devices have been implanted for neurological and neuropsychiatric disorders. This year’s meeting was focused on advances in the following areas: neuromodulation in Europe, Asia, and Australia; cutting-edge technologies, closed loop DBS, DBS tele-health, neuroethics, lesion therapy, interventional psychiatry, and adaptive DBS.

show abstract

Methylphenidate effects on a clinically informative oscillatory signal within the subthalamic nucleus in Parkinson's disease during deep brain stimulation programming

Cited by 4 publications

References 10 publications

Diurnal fluctuations of local field potentials follow sleep-wake behavior in Parkinson's disease

Diurnal fluctuations of local field potentials follow sleep-wake behavior in Parkinson's disease

Proceedings of the 11th Annual Deep Brain Stimulation Think Tank: pushing the forefront of neuromodulation with functional network mapping, biomarkers for adaptive DBS, bioethical dilemmas, AI-guided neuromodulation, and translational advancements

Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation

Contact Info

Product

Resources

About